NEW WEBSITE We would like to invite you to a sneak peak of our new website before it goes live. Visit the new site
« ALL INFRASTRUCTURE SERVICES

Plasma Profiling

National facility

The Plasma Profiling Facility offers a long-standing expertise in affinity proteomic analysis of human body fluids. Our services aim to support researchers and clinicians in the fields of translational and personalized medicine. We provide access to an exquisite infrastructure to apply cutting edge immunoassays technologies for multiplexed protein quantification.

With our expertise, we support biomarker studies from discovery to validation, in a large number of samples and a variety of human conditions. Our services include all aspects such as  study design, selection of antibodies, antibody validation, data processing and statistical analysis. And we also develop alternative assays tailored for the specific needs of the user's projects.

The facility hosts a unique combination of several advanced technologies and has direct access to more than 50,000 antibodies from the Human Protein Atlas.

Do you want to learn more about our technologies? Do you have an exciting project idea?

CONTACT US to discuss the optimal solutions for you!

e-mail | plasma.profiling@scilifelab.se       Twitter | @plasmaprofiling


EATRIS

The Plasma Profiling facility is now part of the Biomarker platform within the European infrastructure for translational medicine (EATRIS). EATRIS is a non-profit European Research Infrastructure Consortium (ERIC) which aims to facilitates collaboration among researchers, physicians, and developers and supports the establishment of multidisciplinary projects in the field of personalised medicine.

plasma profiling facility @eatris.eu


NEWS

We recently expanded our portfolio and installed in January 2020 a new instrument:  SIMOA SR-X, Quanterix®. Simoa® ultra-sensitive immunoassay technology will give us the capability to quantify very low abundant biomarkers in low sample volume.

SERVICES

Highly multiplexed and high-throughput protein profiling of human body fluids

  • Proximity Extension Assays (Certified service provider for Olink Proteins AB)
  • Multiplexed sandwich immunoassay (Commercial kits for Luminex System)

Advanced protein quantification in body fluids

  • Automated microfluidic immunoassays (ProteinSimple)
  • Ultrasensitive immunoassays (Quanterix®)
  • Development of novel quantitative immunoassays (Homebrew Luminex and Quanterix® systems )

Consultation for immunoassays

  • Selection of antibodies and targets
  • Antibody validation
  • Multiplexed assessment of optimal antibody pairs (Luminex System)

Experimental design and data analysis

  • Study design
  • Processing and analysis of affinity proteomics data
  • Statistical and bioinformatics analysis pipeline

APPLICATIONS

  • High-throughput, exploratory protein profiling of human body fluids
  • Biomarkers discovery and validation in large sample cohorts
  • Robust protein quantification for candidate biomarkers
  • Development of novel immunoassays concepts
  • Antibody validation and selectivity analysis

 

 

EQUIPMENT

Reagents

  • 50,000 antibodies from the Human Protein Atlas project

Analytical equipment

  • 2x FLEXMAP 3D, Luminex®
  • LX200, Luminex®
  • MAGPIX, Luminex®
  • ELLA, ProteinSimple®,
  • Biomark HD, Fluidigm®
  • SIMOA SR-X, Quanterix®

Liquid handling equipment

  • FLUENT, Tecan
  • 2x EVO150, Tecan
  • SELMA, CyBio®

Magnetic bead handling equipment

  • KingFisher Flex, Thermo
  • EL406 Washer Dispenser, Biotek
  • Simoa Microplate Washer system, Quanterix®

RECENT PROJECTS

Research Projects:

  • Profiling 400 plasma samples for 1100 proteins using Olink ® technology for the discovery of protein-signatures in health and disease states
  • Evaluation and translation of a novel immunoassay for a cancer-related biomarker.
  • Profiling 3,000 plasma samples using a customized bead array with HPA antibodies for the discovery of disease-associated proteins. The aims are to identify and validate potential biomarkers; (1) to stratify populations by risk of disease progression, and (2) to monitor organ function in response to treatment.
  • Design of a new immunoassay to study proteins for their involvement in protein-protein interactions. We analyzed samples from immuno-precipitations derived from transfected human cells.
  • Development of a new immunoassay to validate proposed biomarker candidates by analyzing lysates of cells collected from cancer patients.

 

Examples of Protein Profiling Publications:

  • Protein profiling and network enrichment analysis in individuals before and after the onset of rheumatoid arthritis. Brink et al. Arthritis Research & Therapy 2019 [PMID: 31842970]
  • Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.Bedri et al. PLoS One. 2019 [PMID: 31141529]
  • A High-throughput Bead-based Affinity Assay Enables Analysis of Genital Protein Signatures in Women At Risk of HIV Infection. Månberg et al., Mol Cell Proteomics. 2019 [PMID: 30504243]
  • CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia. Lind et al., J Pain Res. 2019 [PMID: 31686904]
  • Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. Idborg et al., Front Immunol. 2019. [PMID: 31141529]
  • Stereotypic Immune System Development in Newborn Children, Olin et al., Cell, 2018. [PMID: 30142345]
  • Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci. Drobin et al., Inflamm Bowel Dis, 2018. [PMID: 30358838]
  • Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. Byström et al., Breast Cancer Res, 2018. [PMID: 29444691]
  • Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage Matic et al., JACC Basic Transl Sci, 2018. [ PMID: 30175270]
  • Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury. Mikus et al., Liver International, 2017. [PMID: 27224670]
  • PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Bruzelius et al., Blood, 2016. [PMID: 27742707]

 

Examples of Technology Development Publications

  • The human secretome. Uhlén et al., Sci Signal. 2019. [PMID:31772123]
  • Mass Spectrometry-Based Plasma Proteomics: Considerations from Sample Collection to Achieving Translational Data. Ignjatovic V et al., J Proteome Res. 2019.[PMID:31573204]
  • Multiplexed analysis of the secretin-like GPCR-RAMP interactome. Lorenzen E et al., Sci Adv. 2019. [PMID: 31555726]
  • Systematic Development of Sandwich Immunoassays for the Plasma Secretome. Häussler RS et al., Proteomics. 2019. [PMID: 31278833]
  • Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles. Fredolini C et al., Sci Rep. 2019. [PMID: 31171813]
  • Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Andersson A et al., Clin Chim Acta. 2019. [PMID: 30858094]